StockData

Vanda Pharmaceuticals Inc. (VNDA) stock

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3056% below fair value
$3.81+0.00 (0.00%)

Close on Nov 17, 2026Market cap $230.39MP/E –Yield –

Vanda Pharmaceuticals Inc. grew revenue 8.1% to $229.28M over the twelve months to Sep 30, 2026. Free cash flow was -$139.96M. At the latest close the market valued the company at $230.39M.

Revenue
$229.28M
+8.1% vs. a year earlier
Operating income
-$177.91M
TTM Q3 2026
Free cash flow
-$139.96M
TTM Q3 2026
EPS, diluted
-$4.62
TTM Q3 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026

Valuation

Market cap
$230.39M
P/E ratio
–
Price to sales
1.00
Price to book
1.15
Dividend yield
–
Free cash flow yield
-60.75%

Fundamentals

Revenue
$229.28M
Net income
-$274.83M
EPS, diluted
-$4.62
Free cash flow
-$139.96M
Book value per share
$3.31
Diluted shares
60M

Trading

Next earnings
Feb 10, 2027 (estimated, after the close)
Previous close
$3.81
Open
$3.81
Day's range
$3.78 – $3.90
Volume
830,314
Average volume (20 days)
1,313,199
Index membership
Russell 2000, Russell 3000
52-week range
$3.56 – $9.94
RSI (14 days)
40.6
Volatility (1 year)
80.5%
Relative volume
0.81×

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2010, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodVNDAS&P 500DifferenceVNDA per yearS&P 500 per year
1 month-5.5%-4.0%−1.4 pts
3 months-27.6%-5.0%−22.6 pts
Year to date-56.8%+8.2%−65.1 pts
1 year-13.4%+11.2%−24.6 pts
3 years+7.3%+68.5%−61.2 pts+2.4%+19.0%
5 years-78.5%+67.3%−145.8 pts-26.5%+10.8%
10 years-77.7%+291.6%−369.3 pts-13.9%+14.6%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

$229.28M+8.1% YoY

Gross profit

$214.57M+7.1% YoY

Operating income

-$177.91M

Net income

-$274.83M

EPS, diluted

-$4.62

Free cash flow

-$139.96M
Reported periodTrailing twelve months

Press releases

Releases Vanda Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Vanda Pharmaceuticals

Pharmaceutical Preparations

Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for central nervous system disorders and other medical conditions. Its commercial product lineup includes Fanapt for schizophrenia and bipolar I disorder, Hetlioz for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome sleep disturbances, Ponvory for relapsing forms of multiple sclerosis, and Nereus for motion-induced vomiting. The company operates in a product segment and distributes its medications primarily to wholesale drug distributors and specialty pharmacies.

Company profile, executives and history

Vanda Pharmaceuticals stock: common questions

What is Vanda Pharmaceuticals's stock price?

VNDA closed at $3.81 on Nov 17, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $3.56 and $9.94.

What is Vanda Pharmaceuticals's market cap?

Vanda Pharmaceuticals was worth $230.39M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is VNDA's P/E ratio?

Vanda Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$4.62), so it has no meaningful P/E ratio.

How much revenue does Vanda Pharmaceuticals make?

Vanda Pharmaceuticals reported revenue of $229.28M for the twelve months to Sep 30, 2026, up 8.1% from a year earlier.

Does Vanda Pharmaceuticals pay a dividend?

No. Vanda Pharmaceuticals has not paid a cash dividend over the last twelve months.

When does Vanda Pharmaceuticals report earnings next?

Vanda Pharmaceuticals is expected to report Q4 FY2026 results on Feb 10, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has VNDA stock performed over the past year?

Including dividends, VNDA returned -13.4% over the past year, against +11.2% for the S&P 500.

How many VNDA shares are sold short?

8M shares were sold short at the latest FINRA report, 13.89% of the float, or 5.9 days of average trading volume.

Who are Vanda Pharmaceuticals's competitors?

Companies most similar to Vanda Pharmaceuticals by business, industry and size include AXSM, SNDX, XERS, AMRN, ZVRA.

See a number that looks wrong?